secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001213900-26-026646
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal 12-LOX inhibitor CAD-1005 shows preclinical benefits in obesity and Type 2 diabetes
--------------------------------------------------------------------------------

- Preclinical data: CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, and lowered inflammatory cells in adipose/pancreatic tissues.
- CAD-1005 also evaluated for HIT; Phase 2 trial reduced thrombotic events. Company acquired 12-LOX portfolio in Dec 2025.
- Company believes CAD-1005 is the only clinical-stage 12-LOX inhibitor and may complement GLP-1 obesity drugs.
- CEO highlights broader potential of 12-LOX inhibition beyond HIT; interested in partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026026646/0001213900-26-026646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026026646/ea0281315-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-026646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer